EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer

Fangdi Sun, Seema Nagpal, Surbhi Singhal, Joel W Neal, Heather A Wakelee, Nathaniel J Myall, Patrick Bolan, Jonathan W Riess, David R Gandara, Millie S Das

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.08.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Fangdi Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Stanford University, Stanford, CA. Electronic address: sunf@stanford.edu. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: EGFR-mutated (EGFRm) NSCLC is associated with high incidence of brain metastases and leptomeningeal disease (LMD), for which effective systemic options beyond osimertinib 80 and 160 mg daily are limited. While there is some evidence for high-dose pulse administration of earlier-generation EGFR tyrosine kinase inhibitors (EGFK-TKIs), data for pulse-dose osimertinib are limited. METHODS: This multicenter retrospective case series included patients with EGFRm NSCLC with LMD or parenchymal brain metastases treated with pulse-dose osimertinib (400-560 mg once every 5-7 days) for central nervous system (CNS) progression, with or without other concurrent therapies. CNS disease control was defined as the interval from pulse-dose osimertinib initiation to radiographic progression or discontinuation for clinical progression, whichever was shorter. RESULTS: Among 14 patients, EGFR mutations included exon 19 deletion in 6, L858R in 6, and other mutations in 4. All had received previous EGFR-TKI including 5 with prior osimertinib 160 mg daily. Seven received pulse-dose osimertinib as monotherapy, while the remainder received it in combination with other systemic therapy and/or CNS radiation. No treatment-related severe or unexpected side effects were reported, and only 1 patient required dose modification for adverse events. Median duration of CNS control was 4.0 months (95% CI, 1.8-NR) and median overall survival was 6.2 months (95% CI, 3.2-NR), with benefit driven by patients without previous osimertinib 160 mg daily exposure. CONCLUSION: Though further pharmacokinetic investigation is warranted, this report provides preliminary evidence that pulse-dose osimertinib may be a safe regimen among patients with EGFRm NSCLC and refractory CNS disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsBrain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsMeningeal CarcinomatosisMeningeal NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedErbB ReceptorsFollow-Up StudiesMutationPrognosisProtein Kinase InhibitorsRetrospective StudiesIndolesPyrimidines

Stichwörter der Autor:innen

CNS metastasesCNS progressionEGFR TKIHigh-dose pulseTyrosine kinase inhibitor

Substanzen

AcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsosimertinibProtein Kinase InhibitorsIndolesPyrimidines

Autor:innen und Institutionen

  • Division of Oncology, Department of Medicine, Stanford University, Stanford, CA. Electronic address: sunf@stanford.edu.
  • Department of Neuro-Oncology, Stanford University, Stanford, CA.
  • Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, CA.
  • Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.
  • Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., & Das, M. S. (2025). Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.08.002

Vancouver

Sun F, Nagpal S, Singhal S, Neal JW, Wakelee HA, Myall NJ, et al. Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.08.002

BibTeX
@article{Sun2025,
  author = {Sun, Fangdi and Nagpal, Seema and Singhal, Surbhi and Neal, Joel W and Wakelee, Heather A and Myall, Nathaniel J and Bolan, Patrick and Riess, Jonathan W and Gandara, David R and Das, Millie S},
  title = {Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.08.002}
}
Kostenlos starten →